MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America’s mining sector. The company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation in large enterprise environments, according to a recent article.
Leyton brings extensive experience in national drug policy and workplace safety, having helped design and implement Chile’s ‘Zero Tolerance’ alcohol-impaired driving law as part of the country’s alcohol prevention framework. He also played a role in establishing Chile’s roadside drug testing program introduced in 2019. His appointment reflects MindBio’s strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is closely tied to workplace safety and compliance requirements.
The company’s AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. MindBio is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for detection of drug and alcohol intoxication in a range of enterprise environments, including the mining industry, aviation, construction, and law enforcement. The platform is designed to provide non-invasive, real-time impairment screening to enhance safety protocols.
South America’s mining sector presents a significant opportunity for MindBio, given the region’s emphasis on workplace safety and regulatory compliance. Chile, in particular, has stringent laws regarding alcohol and drug impairment in the workplace, making it a natural entry point for the technology. The appointment of Leyton, who has deep knowledge of local regulations and policy frameworks, positions MindBio to navigate the complex regulatory landscape and accelerate adoption.
The article highlighting MindBio’s progress is available at https://ibn.fm/JBNVq. The company’s latest news and updates are accessible at https://ibn.fm/MBQIF.
